MRI Anatomy of Schizophrenia
精神分裂症的 MRI 解剖
基本信息
- 批准号:8195955
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-10-01 至 2014-09-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdolescentAffectAgeAnatomyAntipsychotic AgentsAreaAuditoryAwardBrainBrain DiseasesBrain PathologyBrain regionBudgetsCaringCell NucleusCerebrospinal FluidChronicChronic SchizophreniaClinicalCommunitiesComplementDataDefectDevelopmentDiagnosticDiseaseDoseEvaluationEvent-Related PotentialsFemaleGenderGeneral PopulationGenerationsGoldGrantHandednessHealthHealth Care CostsHospitalizationHospitalsIntervention TrialInvestigationKnowledgeLanguageLeadLinkLiquid substanceLiteratureLithiumLobeLongitudinal StudiesMRI ScansMagnetic Resonance ImagingManualsMeasuresMethodsModelingMood stabilizersMorbidity - disease rateN-MethylaspartateNeurobiologyOnset of illnessOutcomeParental AgesPatientsPharmaceutical PreparationsPharmacological TreatmentPhysiciansPredictive ValueProcessProtocols documentationPsychiatristPublicationsRecruitment ActivityRecurrenceReportingResearchResearch MethodologyResearch PersonnelRoleSamplingScanningSchizophreniaSigns and SymptomsSocioeconomic StatusSourceSubgroupSuperior temporal gyrusSymptomsTechniquesTemporal LobeTestingTherapeuticTimeValproic AcidVentricularVeteransWorkage groupbasecingulate gyruscompliance behaviordesigndosagefirst episode schizophreniafollow-upfrontal lobegamma-Aminobutyric Acidgray matterindexinginterestlateral ventriclemaleneocorticalneural circuitneurophysiologyneuropsychologicalneurotransmissionnon-complianceprospectiveprotective effectpsychosocialpublic health relevanceresearch clinical testingsevere mental illnesswhite matterwhite matter change
项目摘要
DESCRIPTION (provided by applicant):
Background: For many years the serious mental illness of schizophrenia was thought of as the consequence of abnormalities in development which emerged in the course of adolescent brain development, but whose brain abnormalities did not change after onset. Now, however a new paradigm of post-onset progression of loss of brain gray matter and concomitant increase of brain fluid spaces (CSF) visible on structural MRI scans has become a hot topic in schizophrenia research. As well as other studies, our current Merit award-sponsored longitudinal MRI study and its 68 publications provide strong preliminary evidence of progression. Still, many questions remain. Not all investigators agree on progression of gray matter loss as a part of schizophrenia, and the role of treatment medication in progressive brain changes is controversial. Research Methods: To answer key questions about progression, we propose a 5 year longitudinal naturalistic study in two groups, first episode schizophrenia (FESZ) and chronic schizophrenia (CSZ), both compared with equal numbers of healthy controls (HC) matched on age, gender and parental socio- economic status who will have the same longitudinal protocol; all subjects will have 3T MRI scans. FESZ will have MRIs and clinical/diagnostic evaluations: at 1) onset, objectively defined as first hospitalization (N=110 total over 5 years); 2) 6 months after initial scan (N=63 total); 3) 12 months after initial scan (N=40 total); and 4) 30 months after initial scan (N=20 total). The FESZ subject numbers at each time point reflect both our documented follow-up return rate and the duration constraints of a 5 year study and are based on 22 new FESZ entering each year of the study. We will use the gold standard of manual Region of Interest analysis of MRI scans together with clinical symptom/sign measures to provide answers to key questions. To facilitate comparison FESZ and CSZ will receive the same initial and follow-up clinical and neuropsychological evaluations. Medication status will be tracked monthly by the treating physician and compliance, dosage and load will be tracked for association with MRI/clinical changes. An important feature of this naturalistic study is that power calculations based on preliminary data indicate the FESZ sample N will be large enough to permit subgrouping on the basis of medication, gender and other variables. We will use three measures of onset, the schizophrenia onset scale, medication onset and first hospitalization and will determine which provides the best measure of onset, based on predictive value for MRI changes. Hypotheses: We hypothesize, based on preliminary data, that post-onset progression is most rapid in FESZ in the first 6 months after onset, compared with 28 CSZ at initial and at 30 month follow-up. In FESZ we expect gray matter progressive loss in widespread neocortical areas, most intense in frontal and temporal lobe, and, within these lobes, most intense and rapid in particular brain regions linked to SZ functional abnormalities, such as, for example, in superior temporal gyrus language and auditory processing regions, where it will be associated with progression of clinical symptoms of disorganization and thought disorder. We expect antipsychotic medication to slow progression of both gray matter loss & clinical symptoms while mood stabilizers will slow gray matter progression but will have lesser effect on clinical symptoms.
PUBLIC HEALTH RELEVANCE:
Significance: Our preliminary findings of a rapid post-onset progression of MRI changes in FESZ, if confirmed by the proposed study, would alter our conceptualization of the disorder, and suggest the need for intensive pharmacologic and psychosocial intervention trials at disease onset. Moreover, our study will help define which pharmacological treatments protect against progression. In addition to this potential reformulation of our understanding of progressive brain pathology in schizophrenia, the work proposed will increase our knowledge about what areas of the brain are affected in schizophrenia, an important contribution in its own right. Relevance to Veterans Health: Schizophrenia affects 1% of the general population and is one of the major sources of suffering, morbidity and expense in the VA. In fact, the 100,000 patients treated with schizophrenia each year account for nearly 12% of VA healthcare costs. Increase in knowledge about the brain areas underlying schizophrenia will lead to improvement in treatment and care for afflicted veterans.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert W McCarley其他文献
P300 as An Index of Transition to Psychosis and of Remission: Data from A Clinical High Risk for Psychosis Study and Review of Literature.
P300 作为向精神病转变和缓解的指标:来自精神病临床高风险研究和文献综述的数据。
- DOI:
10.1016/j.schres.2019.02.014 - 发表时间:
2020 - 期刊:
- 影响因子:4.5
- 作者:
Yingying Tang;Junjie Wang;Tianhong Zhang;Lihua Xu;Zhenying Qian;Huiru Cui;Xiaochen Tang;Huijun Li;Susan Whitfield-Gabrieli;Martha E Shenton;Larry J Seidman;Robert W McCarley;Matcheri S Keshavan;William S Stone;Jijun Wang;Margaret A Niznikiewicz - 通讯作者:
Margaret A Niznikiewicz
Robert W McCarley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert W McCarley', 18)}}的其他基金
Basal Forebrain Cellular Mechanisms of Cortical Activation
皮质激活的基底前脑细胞机制
- 批准号:
8242210 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Basal Forebrain Cellular Mechanisms of Cortical Activation
皮质激活的基底前脑细胞机制
- 批准号:
8413399 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Basal Forebrain Cellular Mechanisms of Cortical Activation
皮质激活的基底前脑细胞机制
- 批准号:
8598052 - 财政年份:2011
- 资助金额:
-- - 项目类别:
PROJECT 3: ELECTROPHYSIOLOGICAL & GRAY MATTER MARKERS & PREDICTORS OF PROGRESSION
项目 3:电生理学
- 批准号:
8136028 - 财政年份:2010
- 资助金额:
-- - 项目类别:
相似海外基金
Understanding How Adolescent Bullying Experiences Affect Traumatic Stress,Sexual Health and STI Risk among Men Who Have Sex with Men (MSM)
了解青少年欺凌经历如何影响男男性行为者 (MSM) 的创伤性压力、性健康和性传播感染风险
- 批准号:
10553263 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Understanding How Adolescent Bullying Experiences Affect Traumatic Stress,Sexual Health and STI Risk among Men Who Have Sex with Men (MSM)
了解青少年欺凌经历如何影响男男性行为者 (MSM) 的创伤性压力、性健康和性传播感染风险
- 批准号:
10347813 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Visuocortical Dynamics of Affect-Biased Attention in the Development of Adolescent Depression
青少年抑郁症发展过程中情感偏向注意力的视觉皮层动力学
- 批准号:
10380686 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Visuocortical Dynamics of Affect-Biased Attention in the Development of Adolescent Depression
青少年抑郁症发展过程中情感偏向注意力的视觉皮层动力学
- 批准号:
9888437 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Visuocortical Dynamics of Affect-Biased Attention in the Development of Adolescent Depression
青少年抑郁症发展过程中情感偏向注意力的视觉皮层动力学
- 批准号:
10597082 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Targeting maladaptive responding to negative affect in adolescent cannabis users
针对青少年大麻使用者的负面影响的适应不良反应
- 批准号:
9371970 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Childhood positive affect and anger as predictors of adolescent risky behavior
童年积极影响和愤怒是青少年危险行为的预测因素
- 批准号:
9139461 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Do State Marijuana Policies Affect Adolescent Marijuana and Alcohol Use?
州大麻政策会影响青少年大麻和酒精的使用吗?
- 批准号:
8783159 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Do State Marijuana Policies Affect Adolescent Marijuana and Alcohol Use?
州大麻政策会影响青少年大麻和酒精的使用吗?
- 批准号:
8853783 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Assessment of Affect Instability in Adolescent Girls with BPD Features
具有 BPD 特征的青春期女孩的情绪不稳定评估
- 批准号:
8122499 - 财政年份:2011
- 资助金额:
-- - 项目类别: